November 18, 2017 |
CUMC Researchers Identify Key Molecular Pathways Leading to Alzheimer's
August 20, 2013  | 

New York, NY - Columbia University Medical Center (CUMC) is an internationally recognized leader in the creation of new knowledge and therapies to improve health in individuals and populations. With sponsored research totaling more than $600 million annually, the faculty has had the opportunity to pursue research that encompasses all areas of contemporary biomedical investigation and public health including Nobel-winning developments in cardiac catheterization, the use of dilantin to treat epilepsy, development of the antibiotic bacitracin, identification of cystic fibrosis, discoveries about how memory is stored in the brain and much more.

Another recent discovery from the researchers at CUMC was the identification of key molecular pathways that ultimately lead to late-onset Alzheimer's disease. The study, published in the journal Nature, presents a new approach to Alzheimer’s disease research and highlights several new potential drug targets. 

Much of what is known about Alzheimer's comes from laboratory studies of rare, early-onset, familial (inherited) forms of the disease. “Such studies have provided important clues as to the underlying disease process, but it’s unclear how these rare familial forms of Alzheimer’s relate to the common form of the disease,” said study leader Asa Abeliovich, MD, PhD, associate professor of pathology and cell biology and of neurology in the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain at CUMC. “Most important, dozens of drugs that ‘work’ in mouse models of familial disease have ultimately failed when tested in patients with late-onset Alzheimer's. This has driven us, and other laboratories, to pursue mechanisms of the common form of the disease.” Continue>

Page | 1 2 3 4
Suggested Articles